Please ensure Javascript is enabled for purposes of website accessibility

Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis

By Eric Volkman - Updated Jan 22, 2021 at 4:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.

Bank of America (BAC -1.71%) released a new survey today on the coronavirus vaccines now in use, and the companies behind them, putting a number on the potential sales of the high-demand medications.

According to the bank's estimates, Moderna (MRNA -4.97%) stands to reap around $11 billion on global sales of its vaccine in 2021. The team of Pfizer (PFE 3.59%) and BioNTech (BNTX -2.90%) should do marginally better, earning $11 billion to $12 billion, excluding China.

Both Moderna's mRNA-1273 and Pfizer/BioNTech's BNT162b2 (known under the brand name Comirnaty in Europe) have been authorized for emergency use in the U.S. and the 27-country European Union, among other jurisdictions.

Doctors surveyed by Bank of America collectively believe that around 74% of their patients will be inoculated by the end of this year. The bank noted that this was a higher figure than measured in the last vaccination survey, taken in November.

Child getting a jab from a medical professional.

Image source: Getty Images.

As for vaccine preference, Bank of America analyst Tazeen Ahmad wrote that "Interestingly, [the doctors surveyed] expect 50% of their patients will be on mRNA-1273 by mid-2021, followed by Comirnaty at 32% and others (e.g. AZN, JNJ) at [approximately] 20%, after factoring in considerations of ultra-cold storage requirement and vaccine availability."

The two "others" Ahmad refers to are AstraZeneca and Johnson & Johnson.

Moderna's mRNA-1273 has less-stringent storage requirements than the Pfizer/BioNTech vaccine, which must be kept at ultra-cold temperatures.

Those revenue figures are striking, particularly given that young biotech Moderna's revenue for all of 2019 was barely over $60 million, while BioNTech earned $121.5 million that year. Pfizer, of course, is a far larger company, but $11 billion or so will still have an impact. Its last full-year revenue figure was just under $51.8 billion.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13
Bank of America Corporation Stock Quote
Bank of America Corporation
BAC
$33.86 (-1.71%) $0.59
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.47 (3.59%) $1.82
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$176.98 (1.75%) $3.04
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.21 (2.59%) $1.67
BioNTech SE Stock Quote
BioNTech SE
BNTX
$163.00 (-2.90%) $-4.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.